H.C. Wainwright Initiates Coverage on Summit Therapeutics PLC (ADR)(NASDAQ:SMMT). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Sep 16, 2016.
In a different note, Janney Capital said it Initiates Coverage on Summit Therapeutics PLC (ADR), according to a research note issued on Jun 21, 2016. The shares have been rated ‘Buy’ by the firm.
Summit Therapeutics PLC (ADR) (SMMT) made into the market gainers list on Thursdays trading session with the shares advancing 10.26% or 0.8001 points. Due to strong positive momentum, the stock ended at $8.6, which is also near the day’s high of $8.8173. The stock began the session at $7.7 and the volume stood at 29,943 shares. The 52-week high of the shares is $12.78 and the 52 week low is $4.26. The company has a current market capitalization of $106 M and it has 1,22,96,890 shares in outstanding.
Summit Therapeutics PLC (ADR)(SMMT) last announced its earnings results on Sep 8, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $22.00K. Analysts had an estimated revenue of $320.00K. Earnings per share were $-0.13. Analysts had estimated an EPS of $-0.65.
Summit Therapeutics plc formerly Summit Corporation plc is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company’s lead DMD product candidate is SMT C1100 an orally administered small molecule. The Company’s lead CDI product candidate is SMT19969 an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics Inc. Summit (Oxford) Limited Summit (Wales) Limited and MuOx Limited among others.